Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Receivables (2018 - 2025)

Denali Therapeutics (DNLI) has disclosed Receivables for 8 consecutive years, with $1.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Receivables rose 35.71% to $1.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.9 million, a 35.71% increase, with the full-year FY2024 number at $2.2 million, down 36.52% from a year prior.
  • Receivables was $1.9 million for Q3 2025 at Denali Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $16.8 million in Q2 2021 to a low of $357000.0 in Q2 2022.
  • A 5-year average of $3.3 million and a median of $1.9 million in 2024 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 5495.0% in 2021, then plummeted 97.87% in 2022.
  • Denali Therapeutics' Receivables stood at $1.2 million in 2021, then surged by 657.1% to $9.3 million in 2022, then tumbled by 63.15% to $3.4 million in 2023, then crashed by 36.52% to $2.2 million in 2024, then fell by 12.48% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Receivables are $1.9 million (Q3 2025), $1.4 million (Q2 2025), and $1.7 million (Q1 2025).